Press Release: Novartis receives positive CHMP -2-

References

1. Fowler, NH. et al. Tisagenlecleucel in adult relapsed or refractory

follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325-332.

2. Fowler, NH. et.al. Assessment of Healthcare Resource Utilization and

Costs in Patients with Relapsed or Refractory Follicular Lymphoma

Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the

Elara Study. Abstract #3533. 2021 American Society of Hematology (ASH)

Annual Meeting, Dec 11-14, Atlanta, GA and Virtual.

3. Data on File, Novartis, 2020.

4. Schuster, S., et al. Chimeric antigen receptor T cells in refractory

B-cell lymphomas. NEJM. 2017;377(26):2545--2554.

5. Sutamtewagul, G. & Link, B.K. Novel treatment approaches and future

perspectives in follicular lymphoma. Ther Adv Hematol. 2019; 10:1--20.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Amy Wolf Jackie Stahl

Novartis External Communications Novartis Global Oncology Communications

+41 79 576 0723 (mobile) +1 862 778 0516 (mobile)

Amy.Wolf@novartis.com Jackie.Stahl@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

Julie.Masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +4 16 132 43809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

March 25, 2022 08:03 ET (12:03 GMT)